Life-threatening motor neurotoxicity in association with bortezomib.
Bortezomib has been licensed to be used in relapsed and refractory multiple myeloma. It is a promising agent for this incurable condition but our effort is to caution hematologists about the life-threatening neurotoxicity (grade 4) which was seen in two of six patients treated with this agent although the complication cannot definitely be attributed to bortezomib.
Gupta
Sunil
S
Pagliuca
Antonio
A
Devereux
Steve
S
Mufti
Ghulam J
GJ
Schey
Steve
S
D000368:Aged; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D016638:Critical Illness; D005260:Female; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy; D020258:Neurotoxicity Syndromes / Q000209:etiology*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011719:Pyrazines / Q000009:adverse effects*
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib